AMENDMENT OF SOLICITA	TION/MODIFICATI	ION OF CONTRACT	1. CONTRACT ID CODE	E	PAGE OF	PAGES 2
2. AMENDMENT/MODIFICATION NO. One(1)	3. EFFECTIVE DATE See block 16C.	4. REQUISITION/PURCHASE REQ. NO.  N/A		5. PROJECT	Γ NO. (If app	
6. ISSUED BY CODE	000 010011 1001	7. ADMINISTERED BY (If other than Item	6)	CODE		
National Institutes of Health National Heart, Lung, and Blood Institute 6701 Rockledge Drive, Room 6122 Bethesda, MD 20892-7902		OMB: No.: 0990-0115				
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)			(X) 9A. AMENDMENT OF SOLICITATION NO.			
Recipients of RFP NHLBI-HC-04-19, titled, "Aldosterone Antagonists for the Treatment of Heart Failure with Preserved Systolic Function".			NHLBI-HC-04-19			
			9B. DATED (SEE ITEM 11)			
			7-31-03			
				A. MODIFICATION OF CONTRACT/ORDER NO.		
			10A. MODIFICATION C	OF CONTRACT	T/ORDER NO	).
			10B. DATED (	SEE ITEN	M 13)	
CODE	FACILITY CO	DDE				
11. T	THIS ITEM ONLY APPLIES T	O AMENDMENTS OF SOLICITAT	TONS			
The above numbered solicitation is amended as set forth in	n Item 14. The hour and date specified fo	r receipt of Offers is extended, X	is not extended.			
Offers must acknowledge receipt of this amendment prior to the hou			is not extended.			
		ipt of this amendment on each copy of the offer sul	amitted: or © Ru senarate lette	r or telegram w	hich includes	o reference
to the solicitation and amendment numbers. FAILURE OF YOUR AC	CKNOWLEDGMENT TO BE RECEIVED	AT THE PLACE DESIGNATED FOR THE REC	EIPT OF OFFERS PRIOR TO	THE HOUR A	ND DATE SI	PECIFIED
MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of to the solicitation and this amendment, and is received prior to the o	pening hour and date specified.	ter aiready submitted, such change may be made t	by telegram or letter, provided	each telegram	or letter make	reference
12. ACCOUNTING AND APPROPRIATION DATA (If required)						
13. THIS ITEM APPLIES ONLY TO MODIFICA	ATIONS OF CONTRACTS/OR	DERS, IT MODIFIES THE CONTR	ACT/ORDER NO. A	S DESCRI	BED IN IT	EM
14.						
(X) A. THIS CHANGE ORDER IS ISSUED PURSUAL	NT TO: (Specify authority) THE CHANC	GES SET FORTH IN ITEM 14 ARE MADE IN	THE CONTRACT ORDER N	IO. IN ITEM 1	0A.	
B. THE ABOVE NUMBERED CONTACT/ORDER	R IS MODIFIED TO REFLECT THE AD	DMINISTRATIVE CHANGES (such as changes a	in paying office, appropriation	n date, etc.) SE	T FORTH IN	ITEM
14, PURSUANT TO THE AUTHORITY OF FA	AR 43.103(b).		.,			
C. THIS SUPPLEMENTAL AGREEMENT IS EN	TERED INTO PURSUANT TO AUTHO	RITY OF:				
D. OTHER (Specify type of modification and aut.	thority)		American Indiana			
b. OTTEN (Specify type of modification and auti	noney)					
	sign this document and return	copies to the issuing office.				
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organi		olicitation/contract subject matter where feasible.)				
The following revisions are made to RFP	NHLBI-HC-04-19:					
1. Revise the Table of Contents, item 3. R	Reporting Requirements to	add the following:				
"Reports/Deliverables	toporting requirements to	add the following.				
Item Description	Quantity	Delivery Schedule				
k. Dissemination Plan	1PO; 1 CO	February 15, 2010				
Except as provided herein, all terms and conditions of the document re	eferenced in Item 9A or 10A, as heretofore					
15A. NAME AND TITLE OF SIGNER (Type or print)		16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) Lisa T. O'Neill, Contracting Officer				
		Lisa 1. O Neili, Contracting O	incer			
15B. CONTRACTOR/OFFEROR	15C. DATE	16B. UNITED STATES OF AME	RICA		16C. DA	TE
	SIGNED	0			SIGNED	
		Vit	20-00		-1	1 -
		BY JWa I	1 feel		8/21	103
(Signature of person authorized to sign	1)	(Signature of Cont	tracting Officer)		,	
Signamie of person dumor ted to sign	(Signature of Cont	dennig Officer)				

NSN 7540-01-152-8-70 PREVIOUS EDITION UNUSABLE STANDARD FORM 30 (REV. 10-83)
Prescribed by GSA
F.A.R. (48 CFR) 53.243

RFP NHLBI-HC-04-19, titled, "Aldosterone Antagonists for the Treatment of Heart Failure with Preserved Systolic Function".

Amendment One (1) Page 2 of 2

Description of Technical Progress Reports

k. Dissemination Plan. A dissemination plan provides information about:

How the study investigators will distribute study results (e.g., journal articles, presentations) as well as study intervention materials, if relevant (e.g., patient educational materials, physician guidelines).

Who will receive the information or how materials would be distributed

The process and timing for the distribution

Educational and informational sessions for the public, patients, and providers, as is appropriate for the purpose of the research. (FOR BUDGET PURPOSES: An amount, not to exceed \$100,000, should be used to develop your plan for educational purposes)

NOTE TO OFFERORS:

Policy

If the proposed research has the potential for immediate public health applicability (in general this includes clinical trials, demonstration and education research, but not program project grant applications), requests for permission to submit an offer is required to include a brief (less than one page) description of a dissemination plan that addresses:

Who will be involved

The process to be used to identify, develop, and implement dissemination activities

The types of activities to be used The budget for implementing the dissemination plan The dissemination plan budget is to be included in the last year of requested funding and that dissemination activities may continue under a one-year no cost extension

An explicit statement that the offeror agrees to discuss and finalize the dissemination plan with Institute staff prior to its implementation

2. Revise the Table of Contents, item 2. Background/Statement of Work to correct the following under Phase 2 (Recruitment - 3 years and Follow-up - 2 years (60 months):

Delete: Approximately 5,000 patients will be recruited over 24 months by at least 100 sites.

Insert: Approximately 5,000 patients will be recruited over 36 months with 24 months of follow-up, by at least 100 sites.

3. Revise the Table of Contents, item 11. Instructions Conditions and Notices to Offerors, -Specific to this RFP, under General Information, Estimate of Effort to correct a typographical error as follows:

Delete: Phase II (1 year)

Insert Phase III (1 year)

Phase I (6 Mos) and Phase II (5 years) remain as originally stated.

4. Revise the Table of Contents, item 11. Instructions, Conditions, and Notices to Offerors- Specific to this RFP, General Information to add the following information:

Page and Formatting Limitations

The Technical Plan (objectives, approach, methods, procedures, and schedule) of the Technical Proposal shall not exceed 30 single-sided pages or 15 double-sided pages. This page limitation does not apply to the cover sheet, abstract, table of contents, personnel, facilities, equipment and resources, other considerations, other support, cost information and literature cited. Appendices shall be limited to 50 single-sided pages or 25 double-sided pages. Pages in excess of this will be deleted and will be neither read nor evaluated. Each page of the Technical Proposal must be number sequentially. Offerors are encouraged to limit the overall size of the Technical Proposal, inclusive of appendices, attachments, etc. Note that although there is no page limitation on the Business Proposal, offerors are encouraged to limit its content to only those documents necessary to provide adequate support for the proposed costs.

Type density and size must be 10 to 12 points. If constant spacing is used, 15 cpi (characters per inch) or fewer shall be used whereas proportional spacing should provide an average of no more than 15 cpi. There must be no more than six lines of text within a vertical inch. Margins must be set no less than 2 inch around, exclusive of headers or footers.